Evaluation of external validity of the OVHIPEC ‐1 trial in a real‐world population
International Journal of Gynecology & Obstetrics · 2023-05 · 161 (2) · 640-648
DOI: 10.1002/ijgo.14618 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Gynecology & Obstetrics, online erschienen am 26.12.2022. Verfasst von Ruby M van Stein und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecologic Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Hyperthermia, Induced. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
Objective
The OVHIPEC‐1 trial (Phase III randomised clinical trial for stage III ovarian carcinoma randomising between interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy) showed improved survival when interval cytoreductive surgery (CRS) was combined with hyperthermic intraperitoneal chemotherapy in patients with stage III epithelial ovarian cancer (EOC). The authors compared the control arm of the trial with a real‐world population treated in the Netherlands during the same period to explore generalizability of the trial results.
Methods
For this nationwide comparative cohort study, all patients with EOC undergoing interval CRS between 2007 and 2016 were identified from the Netherlands Cancer Registry if they fulfilled the eligibility criteria of OVHIPEC‐1 ( n = 1376). Patient and treatment characteristics, and overall survival (OS) were compared between trial and real‐world populations.
Results
Age, comorbidity, BRCA status, histologic subtype, and residual disease were similar in trial and real‐world patients. Trial patients had a better performance status, higher socioeconomic status, and underwent bowel surgery more often. In a real‐world setting, patients more often received more than six cycles. The difference in OS between the trial and the real‐world populations was not statistically significant (unadjusted hazard ratio, 1.09 [95% confidence interval, 0.87–1.37]; P = 0.44).
Conclusion
Despite differences in patient characteristics, OS of patients treated in the control arm of OVHIPEC‐1 was similar to patients treated outside the trial. The trial population accurately represents real‐world patients with stage III EOC undergoing interval CRS in terms of outcome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gynecologic Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
- Department of Biometrics, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
- Department of Research & Development, Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, The Netherlands.
- Department of Medical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
ORCID-Profile: Ruby M van Stein
Zitieren
APA
van Stein, R. M., Sikorska, K., van der Aa, M. A., Sonke, G. S., van Driel, W. J., & Dutch OVHIPEC-1 trial group (2023). Evaluation of external validity of the OVHIPEC ‐1 trial in a real‐world population. International Journal of Gynecology & Obstetrics, 161(2), 640-648. https://doi.org/10.1002/ijgo.14618
Vancouver
van Stein RM, Sikorska K, van der Aa MA, Sonke GS, van Driel WJ, Dutch OVHIPEC-1 trial group. Evaluation of external validity of the OVHIPEC ‐1 trial in a real‐world population. International Journal of Gynecology & Obstetrics. 2023;161(2):640-648. doi:10.1002/ijgo.14618
BibTeX
@article{vanStein2023,
author = {van Stein, Ruby M and Sikorska, Karolina and van der Aa, Maaike A and Sonke, Gabe S and van Driel, Willemien J and Dutch OVHIPEC-1 trial group, Dutch OVHIPEC-1 trial group},
title = {Evaluation of external validity of the OVHIPEC ‐1 trial in a real‐world population},
journal = {International Journal of Gynecology & Obstetrics},
year = {2023},
volume = {161},
number = {2},
pages = {640--648},
doi = {10.1002/ijgo.14618}
}
EUVIMED